EP1628672A2 - Zusammensetzung und verwendung von in ätherischen ölen von melaleuca alternifolia oder melaleuca quinquenervia gelöstem reinem jod - Google Patents

Zusammensetzung und verwendung von in ätherischen ölen von melaleuca alternifolia oder melaleuca quinquenervia gelöstem reinem jod

Info

Publication number: EP1628672A2
Authority: EP; European Patent Office
Prior art keywords: grams; melaleuca; composition; iodine; pure
Prior art date: 2003-04-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP04729797A

Other languages

English (en)

French (fr)

Inventor

Denis Mbonimpa

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mkm Scrl

Original Assignee

Mkm Scrl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-28

Filing date

2004-04-28

Publication date

2006-03-01

2004-04-28 Application filed by Mkm Scrl filed Critical Mkm Scrl

2006-03-01 Publication of EP1628672A2 publication Critical patent/EP1628672A2/de

Status Withdrawn legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 45
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 title claims abstract description 42
229910052740 iodine Inorganic materials 0.000 title claims abstract description 42
239000011630 iodine Substances 0.000 title claims abstract description 42
241000366182 Melaleuca alternifolia Species 0.000 title claims abstract description 13
239000000341 volatile oil Substances 0.000 title claims abstract description 13
241000378544 Melaleuca quinquenervia Species 0.000 title claims abstract description 8
208000001688 Herpes Genitalis Diseases 0.000 claims abstract description 18
201000004946 genital herpes Diseases 0.000 claims abstract description 18
238000011282 treatment Methods 0.000 claims abstract description 12
235000009024 Ceanothus sanguineus Nutrition 0.000 claims abstract description 7
235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 7
239000007787 solid Substances 0.000 claims abstract description 6
238000004519 manufacturing process Methods 0.000 claims abstract description 4
238000004090 dissolution Methods 0.000 claims abstract 2
241000378467 Melaleuca Species 0.000 claims description 27
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 25
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 25
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 22
238000009472 formulation Methods 0.000 claims description 13
239000004327 boric acid Substances 0.000 claims description 12
235000011187 glycerol Nutrition 0.000 claims description 12
244000144725 Amygdalus communis Species 0.000 claims description 11
235000011437 Amygdalus communis Nutrition 0.000 claims description 11
239000008168 almond oil Substances 0.000 claims description 10
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 10
241000209140 Triticum Species 0.000 claims description 9
235000021307 Triticum Nutrition 0.000 claims description 9
229920002125 Sokalan® Polymers 0.000 claims description 8
239000000126 substance Substances 0.000 claims description 8
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 7
230000001225 therapeutic effect Effects 0.000 claims description 7
239000000839 emulsion Substances 0.000 claims description 6
238000000034 method Methods 0.000 claims description 6
238000003756 stirring Methods 0.000 claims description 6
229960001631 carbomer Drugs 0.000 claims description 5
239000003921 oil Substances 0.000 claims description 5
235000019198 oils Nutrition 0.000 claims description 5
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
239000013543 active substance Substances 0.000 claims description 4
230000000844 anti-bacterial effect Effects 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 4
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 4
229960002216 methylparaben Drugs 0.000 claims description 4
239000003755 preservative agent Substances 0.000 claims description 4
239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 4
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 4
239000010497 wheat germ oil Substances 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
239000003899 bactericide agent Substances 0.000 claims description 3
230000000855 fungicidal effect Effects 0.000 claims description 3
239000000417 fungicide Substances 0.000 claims description 3
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 3
238000005063 solubilization Methods 0.000 claims description 3
230000007928 solubilization Effects 0.000 claims description 3
239000012873 virucide Substances 0.000 claims description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
239000005642 Oleic acid Substances 0.000 claims description 2
235000021314 Palmitic acid Nutrition 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
VKOBVWXKNCXXDE-UHFFFAOYSA-N ethyl stearic acid Natural products CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
235000020778 linoleic acid Nutrition 0.000 claims description 2
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 2
230000002045 lasting effect Effects 0.000 claims 2
238000010438 heat treatment Methods 0.000 claims 1
208000004898 Herpes Labialis Diseases 0.000 abstract description 4
206010067152 Oral herpes Diseases 0.000 abstract description 4
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 11
239000000243 solution Substances 0.000 description 11
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 8
229940107931 zovirax Drugs 0.000 description 8
229960004150 aciclovir Drugs 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
230000002421 anti-septic effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000006071 cream Substances 0.000 description 3
210000004400 mucous membrane Anatomy 0.000 description 3
238000012360 testing method Methods 0.000 description 3
241001529453 unidentified herpesvirus Species 0.000 description 3
208000003251 Pruritus Diseases 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000035515 penetration Effects 0.000 description 2
WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
244000011376 Leptospermum laevigatum Species 0.000 description 1
235000017865 Leptospermum laevigatum Nutrition 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
208000019802 Sexually transmitted disease Diseases 0.000 description 1
OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
235000010338 boric acid Nutrition 0.000 description 1
229930007050 cineol Natural products 0.000 description 1
229960005233 cineole Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000007803 itching Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012827 research and development Methods 0.000 description 1
238000006748 scratching Methods 0.000 description 1
230000002393 scratching effect Effects 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
241000894007 species Species 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229960003636 vidarabine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses

Definitions

the original feature of the present invention lies, on the one hand, in the use of 1 PURE IODE, in the solid state, which dissolves instantly in the essential oil of Melaleuca Altemifolia (tea tree) and / or Quinquinervia (Niaouli) and, on the other hand, to allow the pure iodine to be contained in a stable and durable emulsion in a strictly dosed formula described below.
the invention is characterized precisely in that the iodine in its pure and solid state dissolves instantaneously while retaining its effectiveness and its stability allowing the optimal use of the properties of iodine in the pure state.
the present invention relates more particularly to the use of this "IODE PUR-MELALEUCA" solution in a formulation whose product is indicated for a general therapeutic treatment for external use and specially indicated in the treatment of labial and genital herpes.
This composition is in the form of gel, lotion, or cream. This new formulation radically treats labial and genital herpes.
the iodine presented in the form of iodine alcohol is very well known for its attributes of bactericide, virucide, fungicide.
the research and experiments carried out by the applicant have resulted in discovering that pure iodine (and not iodine alcohol) dissolves in essential oil of MELALEUCA ALTERNIFOLIA and / or standardized QUINQUINERVIA (following the attached tables) while allowing the iodine to keep its effective attributes by containing it in a stable emulsion.
MELALEUCA (ALTERNIFOLIA and QUINQUINERVIA) comes from the Australian tea tree. Its substance, called Titrol in its raw form and Melasol in aqueous solution, comes from a species of papery bark tree: LE MELALEUCA ALTERNIFOLIA.
Simple herpes type 2 corresponds to genital herpes.
Genital herpes is a sexually transmitted disease characterized by the appearance of bouquet vesicles at the site of inoculation associated with regional lymphadenopathy during primary infection. The hallmark of the infection is the recurrence of vesicles in the same place.
the usual local treatments for herpes are generally carried out using a pharmaceutical composition containing acyclovir or sodium phosphate vidarabine.
This new active substance is mainly intended for the treatment of cold and genital herpes (external use).
the original feature of the present invention lies in the use of pure and therefore solid iodine (and not iodine alcohol) which dissolves in the essential oil of Melaleuca Altemifolia and / or Quinquinervia.
the composition according to the invention is presented in the form of a cream or a transparent gel on the skin.
the pH of the compound is between 3% and 8% and preferably between 3.5% and 7%.
the content of pure iodine is between 1% and 10% and Melaleuca oil between 1% and 30%.
composition may contain, in addition to the "pure iodine-Melaleuca” solution, liquid glycerin, boric acid, wheat germ standardized according to the formulation, explants adapted according to the intended use such as moisturizing agents, propylene glycol, sweet almond oil, neutralizing agents intended to adjust the PH as an example of sodium hydroxide.
"pure iodine-Melaleuca” solution liquid glycerin, boric acid, wheat germ standardized according to the formulation, explants adapted according to the intended use such as moisturizing agents, propylene glycol, sweet almond oil, neutralizing agents intended to adjust the PH as an example of sodium hydroxide.
PURE-MELALEUCA IODE solution - Pure iodine igram dissolved in 2.5 milliliters of Melaleuca Altemifolia (tea tree)
Carbomer in gel form e.g. carbopol gel
the new active substance (according to the above formula) has been tested on cases of acute cold sores: - On cold sores: the product is applied three to four times a day to the area of the skin affected by a patient suffering from an outbreak of HSV-1 and HSV-2 (herpes simplex virus) herpes during the primary infection phase. On the treated lesion of more than 4 cm, we found that from the first application the wound stopped causing pain and the patient stopped scratching. The affected areas are no longer painful or numb. They were no longer hot and itchy. From the first evening, the wound stopped flowing and after 36 hours of treatment (3 to 4 times a day) the wound was dry.
HSV-1 and HSV-2 herpes simplex virus
the invention provides a process for the solubilization of pure Iodine in the essential oil of Melaleuca Altemifolia (tea-tree) / Quinquinervia (niaouli) in any minimum proportion of the Iodine and maximum thereof. .
the invention allows, according to the invented formula, pure iodine to contain itself as a stable emulsion , and to retain its attributes of bactericide, virucide, fungicide, extremely useful in compositions indicated for a therapeutic treatment with external use
the invention relates to a composition intended for treating labial and genital herpes comprising the following components (or the functionally equivalent components) in the ranges of relative ratios indicated below:
Propylene glycol l to 60 milliliters
Glycerin l to 95 grams Wheat germ (*): l to 99 grams
Sweet almond oil 1 to 99 milliliters
Carbomer l to 5 grams
Sx lanette wax l to 50 grams
Boric acid l to 30 grams
the invention relates to a composition intended for treating labial and genital herpes comprising the following components (or the functionally equivalent components) in the range of relative ratios indicated below:
the invention relates to a product specially characterized in that it is obtained by such process described above for a therapeutic treatment for general external use other than the treatment of herpes.
the components below can be part of a composition intended for external therapeutic use. They are present in the ranges of relative reports indicated below:
this formulation can be part of a composition intended especially for treating labial and genital herpes, this composition comprising the following components (or the functionally equivalent components) in the ranges of relative ratios indicated below:

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Virology (AREA)
Medical Informatics (AREA)
Mycology (AREA)
Alternative & Traditional Medicine (AREA)
Botany (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Inorganic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP04729797A 2003-04-28 2004-04-28 Zusammensetzung und verwendung von in ätherischen ölen von melaleuca alternifolia oder melaleuca quinquenervia gelöstem reinem jod Withdrawn EP1628672A2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
BE2003/0265A BE1015498A5 (fr)	2003-04-28	2003-04-28	Composition et utilisation de l'iode pur dissout dans l'huile essentielle de melaleuca alternifolia et/ou de melaleuca quinquinervia.
PCT/BE2004/000059 WO2004096248A2 (fr)	2003-04-28	2004-04-28	Composition et utilisation de l’iode pur dissout dans l’huile essentielle de malaleuca alternifolia et/ou de malaleuca quinquinervia

Publications (1)

Publication Number	Publication Date
EP1628672A2 true EP1628672A2 (de)	2006-03-01

Family

ID=33315071

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP04729797A Withdrawn EP1628672A2 (de)	2003-04-28	2004-04-28	Zusammensetzung und verwendung von in ätherischen ölen von melaleuca alternifolia oder melaleuca quinquenervia gelöstem reinem jod

Country Status (4)

Country	Link
EP (1)	EP1628672A2 (de)
BE (1)	BE1015498A5 (de)
CA (1)	CA2524092A1 (de)
WO (1)	WO2004096248A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA200706401B (en) *	2005-01-20	2008-11-26	Kayban Pty Ltd	Anti-Microbial Agent
IL192335A0 (en) *	2008-06-19	2011-08-01	Avivi Easy Life Ltd	Antiviral compounds
ITRE20090011A1 (it) *	2009-02-11	2010-08-12	Gianni Magnanini	Composizione terapeutica per il trattamento dell'herpes labialis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB589097A (en) *	1945-02-15	1947-06-11	Parisepsin Ltd	Improvements in or relating to the manufacture of antiseptic preparations
DD210384A3 (de) *	1982-09-24	1984-06-06	Pharmazeutisches Werk Halle Bo	Verfahren zur herstellung eines medizinischen schwefelbades mit komplexer wirkung
IT1255450B (it) *	1992-06-30	1995-10-31	Montefarmaco Spa	Uso di acidi biliari come agenti antivirali
US6019941A (en) *	1996-01-30	2000-02-01	Porcello; Joseph A.	Method for disinfecting dermal surfaces and inanimate surfaces, and particularly air ducts
US5972362A (en) *	1997-12-23	1999-10-26	Wenker; Naamah T.	Therapeutic skin preparation
RU2150935C1 (ru) *	1999-06-22	2000-06-20	Московский государственный медико-стоматологический университет	Защитно-профилактический крем
AU2001258714A1 (en) *	2000-05-18	2001-11-26	Albert Evdaev	Herbal composition useful for treatment or oral cavity and method for its local delivery thereof
RU2178290C1 (ru) *	2000-11-22	2002-01-20	Московский государственный медико-стоматологический университет	Защитно-профилактический крем
EP1236466B1 (de) *	2001-02-28	2011-09-21	Axiomedic Ltd.	Feste selbst-haftende Zusammensetzungen zur topischen Behandlung von Störungen der Mundschleimhaut

2003
- 2003-04-28 BE BE2003/0265A patent/BE1015498A5/fr not_active IP Right Cessation
2004
- 2004-04-28 EP EP04729797A patent/EP1628672A2/de not_active Withdrawn
- 2004-04-28 CA CA002524092A patent/CA2524092A1/fr not_active Abandoned
- 2004-04-28 WO PCT/BE2004/000059 patent/WO2004096248A2/fr not_active Ceased

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004096248A2 *

Also Published As

Publication number	Publication date
WO2004096248A3 (fr)	2005-01-13
BE1015498A5 (fr)	2005-05-03
CA2524092A1 (fr)	2004-11-11
WO2004096248A2 (fr)	2004-11-11

Legal Events

Date	Code	Title	Description
2006-01-13	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2006-03-01	17P	Request for examination filed	Effective date: 20051122
2006-03-01	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
2006-04-12	DAX	Request for extension of the european patent (deleted)
2007-03-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2007-05-02	18D	Application deemed to be withdrawn	Effective date: 20061101

Publication	Publication Date	Title
BE891088R (fr)	1982-03-01	Composition a base de peroxyde de benzoyle
WO1984003836A1 (fr)	1984-10-11	Composition dermatologique et son procede de preparation
US5888523A (en)	1999-03-30	Topical non-steroidal anti-inflammatory drug composition
EP3878431A1 (de)	2021-09-15	Kosmetische deodorantzusammensetzung, die zink-ricinoleat enthält
JP2023533169A (ja)	2023-08-02	水アルコールゲル及びゲルの製造方法
EP0055635A1 (de)	1982-07-07	Pharmazeutische Zusammensetzung in Gelform, die Acetylsalicylilsäure enthält
FR2504551A1 (fr)	1982-10-29	Compositions aromatiques possedant des proprietes biologiques et medicaments les renfermant
US7166281B2 (en)	2007-01-23	Pharmaceutical composition and method for relieving itch, pain and swelling resulting from insect bites and stings
US6146640A (en)	2000-11-14	Immune system catalyst
EP2343038B1 (de)	2014-11-26	Dermatologische Zubereitugen enthaltend eine Kombination von peroxydierten Fetten und Zink und Verwendung davon in der Behandlung von unter anderem Herpes.
EP0225831B1 (de)	1991-03-13	Verwendung von hyperoxygenierten Ölen zur Herstellung eines Arzneimittells zur Behandlung von Herpes.
CN1972708A (zh)	2007-05-30	用于局部治疗的组合物
EP1628672A2 (de)	2006-03-01	Zusammensetzung und verwendung von in ätherischen ölen von melaleuca alternifolia oder melaleuca quinquenervia gelöstem reinem jod
EP0225832A2 (de)	1987-06-16	Arzneimittel für die Behandlung von Hämorrhoiden
EP2309981B1 (de)	2013-05-08	Dermatologische zusammensetzung zur behandlung von wundschorf
RU2405535C1 (ru)	2010-12-10	Крем-гель для стоп
EP0465313B1 (de)	1994-10-19	Heilende Zusammensetzung zur örtlichen Anwendung
FR2558058A1 (fr)	1985-07-19	Compositions dermatologiques a usage topique externe, a base de metronidazole utiles pour le traitement de l'acne
EP0391780B1 (de)	1993-08-04	Mittel gegen Juckreiz
RU2203647C2 (ru)	2003-05-10	Гель лечебно-профилактический
FR2504009A1 (en)	1982-10-22	Topical compsns. contg. arnica extract - together with camphor, menthol and surfactant for topical treatment of inflammations and infections
EP0197876B1 (de)	1990-07-11	In der Dermatologie anwendbare und Imidazolidinylurea als aktiven Grundbestandteil enthaltende therapeutische Zusammensetzung
EP1051979B1 (de)	2009-11-04	Verwendung von Peroxidlipiden zur Vorbeugung und/oder Behandlung von irritierenden Effekten eines Wirkstoffes
FR2541895A1 (fr)	1984-09-07	Composition deodorante et antitranspirante a base d'acide triterpenique
EP0865289B1 (de)	2002-02-13	Arzneizubereitungen enthaltend arctium majus